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Abstract
Background: Gliomas are thought to form by clonal expansion from a single cell-of-origin, and progression-associated
mutations to occur in its progeny cells. Glioma progression is associated with elevated growth factor signaling and loss of
function of tumor suppressors Ink4a, Arf and Pten. Yet, gliomas are cellularly heterogeneous; they recruit and trap normal
cells during infiltration.
Methodology/Principal Findings: We performed lineage tracing in a retrovirally mediated, molecularly and histologically
accurate mouse model of hPDGFb-driven gliomagenesis. We were able to distinguish cells in the tumor that were derived
from the cell-of-origin from those that were not. Phenotypic, tumorigenic and expression analyses were performed on both
populations of these cells. Here we show that during progression of hPDGFb-induced murine gliomas, tumor suppressor
loss can expand the recruited cell population not derived from the cell-of-origin within glioma microenvironment to
dominate regions of the tumor, with essentially no contribution from the progeny of glioma cell-of-origin. Moreover, the
recruited cells can give rise to gliomas upon transplantation and passaging, acquire polysomal expression profiles and
genetic aberrations typically present in glioma cells rather than normal progenitors, aid progeny cells in glioma initiation
upon transplantation, and become independent of PDGFR signaling.
Conclusions/Significance: These results indicate that non-cell-of-origin derived cells within glioma environment in the
mouse can be corrupted to become bona fide tumor, and deviate from the generally established view of gliomagenesis.
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Introduction
Gliomas are the most common primary brain tumors,
characterized by the infiltration of neighboring brain structures
and robust expansion during progression to a glioblastoma multiforme
(GBM) [1,2]. Gliomas are frequently characterized by dysregulat-
ed signaling downstream of growth factor receptors such as
EGFR, PDGFR, and IGFR, and elevated production of their
corresponding ligands [3–6]. Nearly 30% of human gliomas show
expression patterns that are correlated with PDGFR signaling [7],
a pattern with prominent expression of OLIG2 and other genes
involved in CNS development referred to as ‘‘proneural’’ [8].
PDGF ligands (A–D) are upregulated in at least a third of surgical
glioma samples and human glioma cell lines [9–13]. The
importance of PDGF signaling is underscored in genetically
engineered rodent gliomas, where overproduction of human
PDGFb ligand is sufficient to induce gliomagenesis in a dose-
dependent manner and allows to recapitulate the histologic,
etiologic and pathobiologic character of the PDGF subset of
human gliomas [14,15]. Additionally, infusion of PDGF into the
ventricles induces proliferation of the SVZ, resulting in lesions with
some characteristics of gliomas [16]. Similar to human gliomas,
mouse gliomas are cellularly and molecularly heterogeneous.
Glioma progression in humans is associated with deletion of the
INK4A/ARF locus and loss of PTEN expression resulting in
activation of Akt [3–6,17]. The standard view of gliomagenesis is
that sequential mutations occur and accumulate in cells derived
from the glioma cell-of-origin. Indeed, many surgical GBM
samples in patients appear clonal, with all tumor cells seemingly
derived from the same cell; however, this may not necessarily
mean they are derived from the cell-of-origin [18–21]. Cellular
heterogeneity and reports of human gliomas comprised of several
genetically unrelated clones suggest the possibility of oncogenic
transformation in cells not derived from the glioma cell-of-origin
[21–26]. The interconversion between human glioma subtypes
upon recurrence and the existence of recurrent gliomas that lack
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the possibility for an expansion of an aggressive clone not arising
from the cell-of-origin [8,27]. In fact, PDGF-induced gliomas
arising in both adult and neonatal rats have been shown to contain
normal stem and progenitor cells ‘‘recruited’’ into glioma mass
and induced to proliferate, indicating that proliferative stem-like
portions of the tumor can arise from normal progenitors.
However, the precise nature and specific functional characteristics
of these ‘‘recruited’’ stem or progenitor cells have not been
described.
Genetic analysis of surgical samples of human gliomas merely
provides retrospective static information with regards to tumor
evolution; lineage tracing from the cell-of-origin cannot be done
in humans. Moreover, identifying and distinguishing GBM cells
from the surrounding stroma is not a trivial task - glioma cells
are often defined histologically, demonstrating high mitotic
indices, expression of stem or progenitor cell markers, abnormal
global gene expression patterns, presence of genetic alterations,
and the ability to serially transplant the disease [3,28,29]. To
investigate cellular contributions and structural/functional
characteristics of ‘‘recruited’’ cells in murine gliomas during
tumor progression, we used RCAS/tv-a and the bacTRAP
systems [30–32]. Defining tumor cells by histologic criteria,
genetic analysis, global gene expression profiling and transplan-
tation studies, we studied the clonality of mouse gliomas with
respect to the cell-of-origin. Here we show that in murine
gliomas induced by human PDGFb (hPDGFb), glioma progres-
sion can occur by expansion of the recruited cells, and that these
cells unrelated to glioma cell-of-origin can be corrupted to
become bona fide tumor.
Results
Murine gliomas contain a recruited cell population
It has been recently shown that gliomas induced in adult or
neonatal rats by hPDGFb-expressing retroviruses contain stem or
progenitor-like cells expressing neural markers, that are contrib-
uting to glioma mass and are induced to proliferate by glioma
environment [15,33]. However, the nature and fate of these cells
not derived from the glioma cell-of-origin has not been extensively
studied. While these cells proliferate and express immature
markers, questions as to whether they are functionally important
in glioma progression, remain dependent from the glioma cell-of-
origin, and whether they represent bona fide tumor cells, have not
been addressed. In order to study this phenomenon of cellular
contribution to glioma heterogeneity, we employed lineage
tracing, molecular analysis and functional characterization of
non-cell-of-origin derived cells using two different mouse models of
hPDGFb-driven gliomas.
We first infected Nestin-tv-a (Ntv-a) mice with an RCAS vector
expressing hPDGFb and eGFP (RCAS-hPDGFb-HA-SV40-
eGFP, ‘‘RCAS-PSG’’) (Figure 1a–i) [14,30,34]. RCAS/tv-a is
a retroviral system that allows for lineage tracing from the nestin-
positive glioma cell-of-origin, and the use of this specific vector
labels the cell-of-origin and its progeny with eGFP expression.
Consistent with the previously published results from others and
us, RCAS-PSG induced high- and low-grade gliomas with typical
oligodendroglioma histology, containing proliferating cells ex-
pressing olig2 and other markers of neural cell lineages
(Figure 1f,g; Figure S1a–d; Figure S2c–f; Figure S3a).
Many but not all of these cells were derived from the cell-of-origin
and expressed viral eGFP (‘‘progeny cells’’), while others appeared
to not be infected with the RCAS-PSG virus (‘‘recruited cells’’), as
they did not express eGFP or hPDGFb, with hPDGFb expression
determined by immunostaining for hemagglutinin epitope tag
included in RCAS-PSG vector (Figure S2a–f) [14–16,33]. In
comparison to the previously published RCAS-hPDGFb vectors,
the levels of hPDGFb expression by RCAS-PSG were 3–4 fold
lower (data not shown) [14]. We confirmed the correlation
between eGFP expression and viral integration using RT-PCR
(reverse transcription), real-time qPCR and FISH in murine
glioma sections and eGFP-positive or eGFP-negative FACS-sorted
glioma cell populations (Figure 1h,i; Figure S1e,f). In these
tumors, histologically-defined pathognomic glioma structures
(secondary structures of Scherer [35]) contained both progeny
and recruited cells (Figure 1b–e; Figure S1a–d). We refer to
these tumors as ‘‘virally-induced gliomas’’.
Modeling systems employing intracranial transplantation of
glioma cells are frequently used in glioma research. To rule out the
possibility of spontaneous proviral excision or loss of eGFP
expression in the originally infected cells in the virally induced
gliomas, we performed transplantations of acutely isolated non-
fluorescent hPDGFb-driven mouse glioma cells derived from Ntv-
a gliomas induced by the non-fluorescent RCAS-hPDGFb vector
into the bacTRAP olig2 RP-eGFP reporter mice, expressing a fusion
between ribosomal protein L10a and eGFP (RP-eGFP) under the
Olig2 promoter (Figure S3b–d) [14,31,32]. In these ‘‘transplanted
gliomas’’, RP-eGFP-expressing host cells represent olig2-positive
recruited cells, while transplanted glioma cells do not express
eGFP. Similar to virally-induced gliomas, RP-eGFP-expressing
host-derived recruited cells proliferated (stained for Ki-67), showed
spindloid and/or typical oligodendroglial morphology, and
contributed to the secondary structures of Scherer (Figure 1j–o).
In virally-induced gliomas, olig2 progeny and olig2 recruited cells are
strictly defined by the presence or absence of eGFP expression; in
contrast, in transplanted gliomas, the injected non-fluorescent
glioma cell population is a mixture of progeny and recruited cells.
Thus, identification of recruited cells by RP-eGFP expression in
this system likely underestimates the true contribution of recruited
cells to the glioma mass. While virally-induced gliomas have been
shown to approximate the human scenario for at least a subclass of
human gliomas, the extent of similarity of transplanted gliomas to
the patient tumors, as well as to other transplantation systems, has
not been addressed [3]. An additional caveat of the bacTRAP
system is that olig2 RP-eGFP expression in the adult murine brain
labels not only progenitor cells, but also more differentiated
oligodendrocytes [32].
Tumor suppressor loss expands the recruited population
As human gliomas progress, loss of tumor suppressor function is
seen in nearly all cases [6]. It is possible that loss of tumor
suppressors in the progeny or the recruited populations during
glioma progression could give a preferential growth advantage to
either of these cell populations. Therefore, to investigate the
relative effects of tumor suppressor loss on progeny and recruited
cells, we induced gliomas in Ntv-a mice with germline deletions of
Ink4a, Arf and/or Pten, the latter achieved by Cre-mediated
recombination of the floxed Pten alleles by RCAS-Cre [36,37]. As
previously published, we found that loss of Arf and Pten, but not
Ink4a, shortened tumor latency and increased incidence of murine
GBMs, histologically defined by the presence of microvascular
proliferation and pseudopalisading necrosis (Figure 2a; Figure
S4a,b) [3,36,37]. Of note, the contribution of the recruited cells to
high-grade glioma structures was most prominent in the Ntv-a
Ink4a/Arf
-/-, Pten
-/- tumors (Figure 2b–f).
We then determined whether such robust expansion of the
recruited cell population upon tumor suppressor loss is limited to
modeling systems characterized by paracrine growth factor
Transformed Recruited Cells
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e20605signaling, or whether it could apply to murine gliomas with cell-
autonomous activation of oncogenes. While mutations in RAS are
not characteristic of a given human glioma subtype, we used
overexpression of mutant RAS as a proxy to model human gliomas
driven in a cell-autonomous manner [38]. For this purpose, we
created RCAS-mRFP-SV40-Ras (RCAS-RSR) vector that ex-
presses mutant KRASG12D and simultaneously marks the infected
cells by expression of mRFP (Figure S5a–e). While this vector
was not robust at glioma initiation (,10% incidence), injections of
RCAS-RSR and RCAS-Cre into Ntv-a Ink4a/Arf
-/-Pten
fl/fl mice
could give rise to high-grade gliomas that did not express
PDGFRa and contained regions of proliferating cells that did
not express mRFP (Figure S5d,e,g).
To further address the ability of the recruited cells characterized
by tumor suppressor loss to contribute to high-grade glioma
structures, we performed transplantation experiments using the
bacTRAP system. Transplantation of non-fluorescent hPDGFb-
driven glioma cells into Ink4a/Arf
-/-Pten
fl/fl bacTRAP olig2 RP-eGFP
reporter mice resulted in formation of high-grade glioma
structures comprised of both progeny and recruited cells (Figure
S5h). Transplanted gliomas induced by hPDGFb-driven glioma
cells in hosts with altered tumor suppressor function showed
higher percentages of the overall recruitment than in the wild-type
hosts, indicating that complete or partial tumor suppressor loss
may enhance the ability of the cells to be recruited (Figure 2g).
Although gliomas induced by transplantation of non-fluorescent
Pten-deleted Ras-driven murine glioma cells showed recruitment of
proliferating host brain cells into the glioma mass (Figure S5f,h),
the overall amount of recruited cells into Ras-driven tumors and
the number of tumors that showed large regions of recruitment
was significantly less than that seen with the hPDGFb-induced
gliomas (Figure 2g).
Figure 1. PDGF-driven murine gliomas contain recruited cells that are not derived from the cell-of-origin. (a–g) Virally encoded eGFP
on DAPI-stained frozen sections of RCAS-PSG-induced wild-type murine Ntv-a gliomas. Yellow arrows in (b–e) show Scherer’s secondary structures,
including subpial accumulations of tumor cells (b), white matter tracking (c), perivascular accumulations of glioma cells (d), and perineuronal
satelliting cells (e). Scherer structures are contributed to by both progeny and recruited cells. Sections in (e,f,g) were stained with NeuN, olig2, and
Ki67, shown in red. Arrows in (f,g) indicate Ki-67 (f) or olig2 (g)-expressing progeny cells (yellow) and recruited cells (pink). (h,i), FISH analysis of
murine glioma sections (h), FACS-sorted eGFP-negative recruited cells (i), and eGFP-positive sorted progeny cells (i, inset). Pink arrows in (h; i inset)
indicate presence of multiple integrations in progeny cells (green signal); note the absence of integrations in recruited cells (white arrows; h,i). Note
that the majority of cells in the tumor section appear recruited, and viral integration correlates with the eGFP expression by FACS. (j–o) Native RP-
eGFP on DAPI-stained frozen sections of bacTRAP gliomas induced by orthotopic transplantation of non-fluorescent hPDGFb-driven primary mouse
glioma cells into the bacTRAP olig2 RP-eGFP reporter mice. Yellow arrows in (k,l) indicate Scherer’s secondary structures, containing RP-eGFP-positive
recruited cells; asterisk in (m) shows the lumen of a large vessel. (n,o) Ki67 staining (red) and CD31 staining (yellow) indicate that most olig2 recruited
cells expressing RP-eGFP in transplanted gliomas proliferate robustly.
doi:10.1371/journal.pone.0020605.g001
Transformed Recruited Cells
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mass during progression
The above data indicates that murine glioma cells, especially
those driven by PDGF signaling, recruit proliferating olig2-
expressing progenitors, and their contribution to high-grade
glioma structures is enhanced upon homozygous loss of Ink4a/
Arf and Pten at glioma initiation. However, human gliomas
undergo tumor suppressor loss stochastically as they progress.
Stochastic tumor suppressor loss could in principle occur in any
cell subjected to the pressures of glioma environment, regardless of
its progeny or recruited status. To mimic this phenomenon, we
used Ntv-a Ink4a/Arf
+/-Pten
+/fl mice infected with RCAS-PSG and
RCAS-Cre. Given the constraints of our experimental system,
formation of murine gliomas with high-grade architectural features
would require loss of function of the remaining tumor suppressor
allele, by either stochastic loss of heterozygosity (LOH) or
epigenetic events. The rarity of such events would in turn result
in the expansion of an altered cell population from a single cell, be
it progeny or recruited. Although neither Ntv-a Ink4a/Arf
+/-Pten
+/fl
nor Ntv-a Ink4a/Arf
-/-Pten
fl/fl mice generate spontaneous gliomas,
it is likely that experimentally provided genetic hits may represent
the rate limiting step for transformation and thus, transformation
of recruited cells may be less common in human gliomas.
While the latency of gliomas induced in Ntv-a Ink4a/Arf
+/-Pten
+/fl
mice by RCAS-PSG and RCAS-Cre was intermediate between the
wildtypeandInk4a/Arf
-/-Pten
fl/flmice,thedistributionofgliomagrades
at the point when the tumors caused mice to become moribund was
similar to that of gliomas characterized by homozygous tumor
suppressor loss at initiation (Figure 2a; Figure S4b). However,
unlike the mixed progeny-recruited cell composition seen in gliomas
null for Ink4a, Arf and Pten at tumor initiation, gliomas arising in
mice initially heterozygous for these tumor suppressors frequently
showed regional domination by either progeny or recruited cells
(Figure 3a–d). In the most extreme cases, such glioma regions were
almost fully comprised of eGFP-negative recruited cells,as verified by
FACS and qPCR (Figure 3a,b,e; Figure S5j,k). Of note, these
regions dominated by recruited cells showed loss of function of the
remaining wild type tumor suppressor alleles by LOH (in the case of
Ink4a/Arf),orlossofexpressionattheproteinlevelwithorwithoutLOH
(in the case of Pten), as in human gliomas (Figure 3f; FigureS4c–e).
While Ink4a/Arf loci were most frequently lost at the genetic level as
determined by PCR, of 40 hPDGFb-driven gliomas arising in Ntv-a
Ink4a/Arf
-/-Pten
fl/fl or Ntv-a Ink4a/Arf
+/-Pten
+/fl injected with RCAS-
Cre,28didnotexpressPten;ofthese,21retainedPtenallelebyreal-time
PCR, while 7 lost it (Figure S4c).Thus, whilelossof Pten expression
occurredin,70%ofallcases,lossofPtenattheDNAleveloccurredin
17.5% cases. There was a small but statistically significant difference
with respect to latency medians depending on whether a given glioma
waspredominantlyderived fromprogenyor recruitedcells (two-tailed
unpaired Student’s t-test, p,0.006) (Figure S5i). However, their
varianceslargelyoverlapped(Ftest),andGBMscontaininglargeareas
with pseudopalisades predominantly comprised of recruited cells
represented,30% of allmouse GBM cases (Figure3g).
Recruited regions of hPDGF-induced gliomas can
become independent of PDGF signaling
We then characterized tumors with regions dominated by
recruited cells for expression of growth factor receptors commonly
Figure 2. Homozygous tumor suppressor loss at glioma initiation enhances tumor formation and expands the recruited glioma cell
fraction. (a) Kaplan-Meyer analysis for symptomatic gliomas in various Ntv-a mouse strains listed above the graph, injected with RCAS-PSG and
RCAS-Cre, if applicable. Each curve represents survival analysis for n$30 animals. (b,c) Quantification of percentages of progeny cells in Ntv-a
gliomas, which are wild-type, deleted for Ink4a/Arf, or for Ink4a/Arf and Pten, as measured by FACS. Tumor suppressor loss expands the recruited
component in mouse gliomas. (d–f) DAPI-stained images of frozen sections of murine gliomas, showing virally encoded eGFP in RCAS-PSG-induced
Ntv-a GBMs deleted for Ink4a/Arf (d,e) or Ink4a/Arf and Pten (f). (g) Quantification of number of transplanted gliomas (z-axis) containing various
percentages of recruited cells (x-axis), induced by transplantation of non-fluorescent hPDGFb-driven or Ras-driven murine glioma cells into the wild-
type or Ink4a/Arf
+/- bacTRAP olig2 RP-eGFP hosts (y-axis). Note that significant recruitment occurs upon transplantation of either hPDGFb-driven and
Ras-driven murine glioma cells into the Ink4a/Arf
+/- hosts.
doi:10.1371/journal.pone.0020605.g002
Transformed Recruited Cells
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[3–5]. In gliomas where both alleles of Ink4a, Arf, Pten were deleted
at tumor initiation, and in regions of gliomas dominated by
progeny in tumors with initially heterozygous deletion of these
tumor suppressors, both progeny cells and recruited cells expressed
PDGFRa, with ,5% tumors co-expressing EGFR (Figure 4e;
Figure S6a–c; data not shown) [14–16,33]. By contrast,
glioma regions primarily comprised of eGFP-negative recruited
cells frequently expressed EGFR or IGFR and not PDGFR
(Figure 4a–e; Figure S6b–d). The primary mechanism for
EGFR and IGFR expression in recruited regions is unclear;
however, low-level amplification of these genes was seen in some
cases. FISH analysis for mouse EGFR of eleven murine gliomas
containing large regions of recruited cells with high expression of
EGFR and/or IGFR showed .2 copies of EGFR in 5 of 11 cases,
while 1 of 11 showed .2 copies of IGFR (Figure S6e,f). qPCR
analysis of a panel of these and 15 other murine gliomas
containing regions comprised of recruited cells was consistent
with amplification of EGFR at the DNA level occurring at most in
6o f1 8( ,30%) of all cases, while IGFR was only amplified at most
in 2 of 19 (,10.5%) (Figure S6g,h).
In hPDGFb-induced gliomas, pharmacologic blockade by the
PDGFR/VEGFR inhibitor PTK787 that crosses the blood-brain
barrier results in cell cycle arrest of the tumor cells; thus, these
gliomas retain their dependence on PDGFR signaling [39]. Since
gliomas with large areas of recruited cells did not express
PDGFRa, we investigated whether recruited cells became
independent of hPDGFb signaling during glioma progression.
We treated ten Ntv-a Ink4a/Arf
+/-Pten
+/fl glioma-bearing mice with
PTK787 for a week at the onset of symptoms; eight mice survived
the full course of treatment. Of these, three mice had gliomas that
expressed PDGFRa and eGFP in high-grade tumor areas,
concomitant with reduced proliferation rates (p,0.0001)
(Figure 4f). Gliomas in the remaining five mice contained
.85% recruited cells in high-grade tumor areas, showing
proliferation rates statistically similar to the untreated tumors
with large areas of recruitment (Figure 4f; data not shown).
Thus, regions dominated by recruited cells became independent of
PDGFR signaling during glioma progression, and the response to
PTK787 treatment was dependent on the cellular composition of a
given glioma. Although PTK787 also targets VEGFR, the
conclusion that recruited glioma regions are independent of
Figure 3. GBMs arising in mice targeted for heterozygous tumor suppressor loss show expansion of either recruited or progeny cell
populations in pseudopalisade regions. DAPI-stained composite (a,b) and 20X (c,d) images of frozen sections showing virally encoded eGFP in
RCAS-PSG-induced Ntv-a GBMs heterozygous for loss of Ink4a, Arf and Pten at tumor initiation, with stochastic tumor suppressor loss in regions of
progeny (a,c) or recruited (b,d) cells during tumor progression. (e) real-time qPCR for viral hPDGFb-HA on tumor cell DNA extracted from mouse
GBMs, indicating much lesser amounts of viral integrations in GBMs containing recruited pseudopalisades (blue squares), as compared to progeny
pseudopalisades (green squares). Graph shows fold change over the background in the uninjected adult mouse brain (Ø); all analyses are normalized
to GAPDH as a control. {, positive control, RCAS-PSG Ntv-a GBMs deleted for Ink4a/Arf and Pten.( f) PCR for viral hPDGFb-HA, wild-type or knockout
Ink4a/Arf loci and Pten alleles on tumor cell DNA extracted from mouse glioma sections. hPDGFb-HA PCR: Ø, negative control, uninjected adult
mouse brain; {, positive control, Ntv-a GBM homozygous deleted for Ink4a, Arf and Pten. GAPDH PCR was done in the same tube. Ink4a/Arf, Pten PCR:
Ø and { indicate controls for wild-type or knockout alleles and loci, respectively (presence of band in KO lane indicates deleted allele). Gliomas that
lost Ink4a/Arf during tumor progression were also likely to lose wild-type Pten allele. (g) Incidence of GBMs containing regions of recruited cells,
progeny cells or a mixture of these cells in pseudopalisade regions, in Ntv-a mice heterozygous targeted for loss of Ink4a, Arf and Pten. While most
GBMs arising in mice heterozygous deleted for Ink4a/Arf and Pten at glioma initiation contain large regions of progeny, about ,30% show large areas
of recruitment (total number of tumors analyzed, n=36).
doi:10.1371/journal.pone.0020605.g003
Transformed Recruited Cells
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the relative lack of cell cycle arrest in the recruited glioma regions.
Recruited cells initiate gliomas upon transplantation and
aid glioma formation by progeny cells
Although glioma patients do not die from glioma cells
transplanted into them but rather from the massive expansion/
infiltration by the glioma cells, tumor cells in rodent systems are
most stringently defined by their ability to form secondary tumors
upon transplantation into recipient mice [40–44]. We isolated
either progeny or recruited cells based on their expression of viral
eGFP by FACS from Ntv-a Ink4a/Arf
-/-Pten
fl/fl or Ink4a/Arf
+/-Pten
+/fl
mice injected with RCAS-PSG and RCAS-Cre (Figure 5a,b;
Figure S7e–h). Single sorting of recruited cells ($98.5% purity)
gaverisetocellfractions thatformedtumorswithlatency,grade and
histology similar to gliomas induced by eGFP-positive progeny, but
showed variable contamination with progeny cells in the resulting
lesions with up to 10% progeny cells (Figure 5d,e; Figure S7a–
d). Double sorting of eGFP-negative cells gave a population that
was $99.5% recruited and formed high-grade gliomas not
contaminated with progeny cells upon transplantation, albeit at a
low frequency and requiring large numbers of transplanted cells
(Figure 5c, 5f–h; Figure S7e–h). While large numbers of
recruited cells were necessary to induce gliomas upon transplanta-
tion, it is important to remember that non-eGFP-expressing cells in
virally-induced gliomas include normal stromal cells types (endo-
thelial cells, astrocytes, macrophages, etc). Transplanted gliomas
arising from stringently gated double-sorted eGFP-negative recruit-
ed cells did not express viral eGFP and had no detectable provirus
by real-time PCR (Figure 5g). Moreover, these gliomas could be
serially passaged (Figure 5i; Figure S7i–l; Table S1). In addition
to EGFR expression and unlike gliomas with the typical
oligodendroglialmorphologyinducedbytransplantationof progeny
cells, these tumors showed regionally high expression of nestin,
GFAP, CD44, vimentin and VEGFR, while expression of olig2 was
variable in some tumor areas and absent in most (Figure S8)[ 8].
Figure 4. Glioma regions dominated by recruited cells can become independent of PDGFR signaling. (a–d) DAPI-stained frozen section
of an Ntv-a RCAS-PSG-induced GBM heterozygous deleted for Ink4a/Arf and Pten at tumor initiation, containing large areas of recruitment expressing
IGFR (b, red) and EGFR (c, white); (d) shows composite. (e) Quantification of growth factor receptor expression in Ntv-a GBMs in homozygous (n=22)
or heterozygous deleted backgrounds, containing large regions of progeny cells (‘‘progeny’’, n=43) or recruited cells (‘‘recruited’’ n=32), by
immunostaining. (f) Percent of Ki67-positive cells in untreated or PTK787-treated Ntv-a GBMs heterozygous deleted at glioma initiation and
containing large regions of progeny (green squares) or recruited (blue squares) cells. Recruited cells in RCAS-PSG-induced Ntv-a GBMs heterozygous
deleted for Ink4a, Arf, Pten at tumor initiation and containing large recruited areas do not reduce their proliferation rates in response to treatment
with PDGFR/VEGFR inhibitor PTK787, suggesting that they become independent of PDGFR signaling.
doi:10.1371/journal.pone.0020605.g004
Transformed Recruited Cells
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some circumstances.
CD133, a pentaspan transmembrane protein and a hemato-
poietic stem cell marker, was reported to label the most
proliferative and robustly tumorigenic cells in human gliomas,
although this has been questioned in different contexts [40,42,44].
We addressed tumorigenic properties of CD133-positive cells in
the context of virally induced hPDGFb gliomas. Purified double-
sorted CD133-positive cells derived from Ntv-a Ink4a/Arf
-/-Pten
fl/fl
or Ntv-a Ink4a/Arf
+/-Pten
+/fl mice injected with RCAS-PSG and
RCAS-Cre were not derived from progeny cells and were all
recruited, as confirmed by RT-PCR, qPCR and FISH on FACS-
sorted cells (Figure 6a–f,h; Figure S9a–d). Moreover, while
transplantation of single-sorted CD133-positive cells resulted in
gliomas contaminated by the eGFP-positive progeny, without the
expansion of progeny cells in some cases (Figure S9e–j;
Figure 6h), transplantation of purified CD133-positive recruited
eGFP-negative cells from Ntv-a Ink4a/Arf
-/-Pten
fl/fl or Ntv-a Ink4a/
Arf
+/-Pten
+/fl mice did not result in glioma formation, suggesting
that in hPDGFb-driven murine gliomas, tumorigenicity lies in the
CD133-negative recruited cell subset (Figure 6g).
We further addressed whether the CD133-positive subset of
recruited cells showed functional importance for initiation or
progression of transplanted hPDGFb-induced murine gliomas by
cell-mixing experiments. While purified CD133-positive recruited
cells could not give rise to transplanted gliomas at 10,000 cells (0/
24 cases), and progeny cells did not robustly form tumors with cell
numbers less than 3,000 (3/20 cases), addition of 10,000 CD133-
positive recruited cells to 1,000 eGFP-positive progeny resulted in
robust gliomagenesis (Figure 6i). Thus, CD133-positive recruited
cells enhanced the ability of the progeny cells to initiate tumors
upon transplantation, with small numbers of CD133-positive
recruited cells sufficient to promote induction of transplanted
tumors, the final mass of which was predominantly derived from
the recruited cells (data not shown).
Recruited cell gene expression resembles tumor cells
An unbiased way to define a cell population lies in identification
of its gene expression signature and subsequent comparison to
gene expression signatures of known normal or cancer cells to
define its position on the axis of tumorigenesis. To quantify
similarities and differences in the expression profiles of recruited
cells and tumor cells using microarray analysis, we used the
bacTRAP technology that allows immunoprecipitation of poly-
somes from specific cell types in vivo (Figure S3a–d) [31,32]. We
compared polysomal expression profiles of hPDGFb-driven Ntv-a
Ink4a/Arf
+/- olig2 mouse glioma cells representing a histologically
defined glioma population, recruited olig2 cells derived from
Figure 5. Recruited cells can form tumors upon transplantation and can be serially passaged in mice. FACS sorting of progeny (a) and
FACS purification of the recruited cells (b,c) from RCAS-PSG-induced Ntv-a gliomas initiated in mice homozygous or heterozygous targeted for Ink4a,
Arf, Pten.( d–f), DAPI-stained frozen sections showing virally encoded eGFP of transplanted gliomas induced by progeny (d), single-sorted recruited
(e), or double-sorted recruited (f) cell fractions. (g) shows real-time qPCR analysis of sorted fractions and a transplanted eGFP-negative glioma
induced by resorted recruited glioma cells. Ø, uninjected adult normal brain; {, Ras-driven Ntv-a glioma. All reactions were normalized to GAPDH.
Graph shows fold change over the background amplification in Ras-driven glioma. (h) Incidence of gliomas induced by transplanting eGFP-positive
progeny or double-purified eGFP-negative recruited cell fractions derived from Ntv-a RCAS-PSG-induced mouse gliomas homozygous or
heterozygous deleted for Ink4a, Arf and Pten at tumor initiation. (i) Incidence of gliomas induced by serial transplantation of the recruited cells.
Recruited cells can be serially passaged in mouse recipients, with a marked increase in frequency of tumor initiation after passage 3.
doi:10.1371/journal.pone.0020605.g005
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+/- olig2 RP-eGFP mice transplanted with non-fluorescent
glioma cells, and normal adult cortical olig2 mouse progenitors,
using Affymetrix 430 mouse 2.0 chips and Genespring GX10
software [31,32]. Translational profiles of recruited olig2 cells and
glioma olig2 cells were similar to each other and clearly distinct
from the normal olig2 progenitors, majority of the differences
accounted for by the ‘‘statistically significantly changed’’ set of
mRNAs (ANOVA, p,0.05), and sample clustering reduced upon
removal of the ANOVA-tested mRNA set (Figure 7a–d; Figure
S10a–c,e). Unsupervised hierarchical mRNA clustering likewise
indicated that recruited olig2 cells clustered more closely to glioma
olig2 cells (Figure 7e). The caveat is that olig2 expression in the
adult normal brain of bacTRAP olig2 RP-eGFP mice labels both
progenitors and mature oligodendrocytes, while recruited and
tumor olig2 cells are almost entirely progenitors; therefore, some
of the differences seen in the comparative analysis of normal,
tumor and recruited olig2 cells may in part result from the shift in
relative abundance of different progenitor and mature olig2 cell
populations.
Pair-wise comparisons indicated that out of 2,593 mRNAs
differentially present on the polysomes, 2,310 mRNAs were
differentially present in glioma vs. normal olig2 cells and 2,262
mRNAs in recruited vs. normal olig2 cells (one-way ANOVA,
p,0.05, SNK post-hoc, FDR correction); of note, 86% (1,979
Figure 6. In RCAS-PSG-induced Ntv-a gliomas, CD133-positive cells are recruited and do not form gliomas upon transplantation,
but contribute to gliomagenesis if co-transplanted with progeny. FACS purification and post-sort analysis of progeny (a,d) and FACS
purification of the recruited CD133-positive cells (b,c) from RCAS-PSG-induced Ntv-a gliomas initiated in mice homozygous or heterozygous targeted
for Ink4a/Arf and Pten.( e,f) FISH analysis for viral integration on the purified eGFP-positive progeny or CD133-positive recruited cells. Red background
in (f) represents the CD133 staining. (g) Incidence of gliomas induced by transplanting eGFP-positive progeny or eGFP-negative CD133-positive
recruited cell fractions derived from Ntv-a RCAS-PSG-induced mouse gliomas homozygous or heterozygous deleted for Ink4a, Arf and Pten at tumor
initiation. (h) real-time qPCR analysis of sorted eGFP-positive cells, single-sorted CD133-positive cells and transplanted gliomas induced by these cell
fractions, derived from Ntv-a gliomas initiated in mice heterozygous targeted for Ink4a, Arf and Pten. Asterisks indicate that transplanted gliomas
induced by single-purified CD133-positive cells do not expand the progeny cell fraction. (i) Incidence of transplanted gliomas induced by injection of
double-purified CD133-positive recruited cells, with or without low numbers of eGFP-positive progeny cells. Neither double-purified CD133-positive
cells derived from RCAS-PSG-induced Ntv-a gliomas initiated in mice homozygous targeted for Ink4a/Arf and Pten at glioma initiation nor low
numbers of eGFP-positive progeny give rise to gliomas on their own; however, addition of low numbers of recruited CD133-positive cells to few
progeny cells allows for robust gliomagenesis.
doi:10.1371/journal.pone.0020605.g006
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(Figure 7d). Ingenuity analysis of this polysomal set revealed
mRNAs implicated in genetic disorders, neurological disease and
cancer, regulating cell death, morphology and the cell cycle (data
not shown). Of 500 mRNAs most different between glioma and
normal olig2 cells, 490 mRNAs were changed in the same
direction but smaller magnitude in recruited olig2 cells, 440 of
which were at least two-fold different, and 183 were five-fold
different or more (Figure S10d). From the above data, the
expression profile of recruited cells closely resembled that of tumor
cells, placing the two closely together in the continuum of change
towards the ‘‘malignant state’’, and further confirming that
recruited olig2 expressing cells are tumor. While only ,300
mRNAs were the same between normal and either glioma or
recruited olig2 cells, the number of mRNAs that were the same
between glioma and recruited olig2 cells was at least three-fold
more, amounting to 1,047 (Figure 7d). Many of these mRNAs
were classified into gene categories listed above by Ingenuity (data
not shown).
Although tumor and recruited olig2 cells were predominantly
similar, the number of differentially recruited mRNAs with over 2-
fold change between tumor and recruited olig2 populations
amounted to 665, and those with over 5-fold change amounted
to 132. mRNAs specifically present on polysomes of olig2
recruited cells coded for proteins in Hedgehog, Wnt, Ras, Rho/
Rac and PLC pathways. While PDGFRa and TGFb mRNAs
were lower in recruited olig2 cells than tumor cells, mRNAs
coding for EGFR, TGFa, TNF, LIF and FGFR1/2 were higher in
recruited cells; prominin1 (CD133) mRNA was 5.3 fold higher in
the recruited than tumor olig2 cells. mRNA populations
corresponding to genes defining oligodendrocytic character were
reduced in olig2 recruited cells, while mRNAs associated with
astroglial and endothelial characteristics were upregulated in the
recruited population. In addition, 41 mRNAs were increased on
Figure 7. Gene expression of recruited olig2 cells resembles gene expression of olig2 glioma cells rather than adult olig2
progenitors. (a,b) Principal component analysis on filtered (a) and ANOVA-tested mRNAs (b) derived from normal olig2 progenitor cells (orange),
glioma olig2 cells (blue) or recruited olig2 cells (brown). (c) Profile plot of non-averaged normalized intensity values of 2,593 ANOVA-tested mRNAs
different between normal, glioma and recruited olig2 cell populations. Most mRNAs change in the same direction in recruited and tumor olig2 cells.
(d) Venn diagrams showing differentially recruited polysomal mRNAs in glioma olig2 cells or recruited olig2 cells versus cortical olig2 progenitors
(Diagram1), or polysomal mRNAs that are the same (Diagrams2,3,4) between indicated olig2 populations. T Olig2, tumor olig2 cells; R Olig2, recruited
olig2 cells; N Olig2, normal adult cortical olig2-expressing progenitors. (e) Unsupervised hierarchical clustering on entities and conditions for N Olig2,
T Olig2 or R Olig2 cells. Samples cluster within groups, and recruited olig2 cells cluster with tumor olig2 cells. (f) Heat map showing ANOVA-tested
mRNAs over 10-fold enriched between recruited and glioma olig2 cell populations, as compared to normal olig2 cells.
doi:10.1371/journal.pone.0020605.g007
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tumor olig2 cells and differentially from normal olig2 cells
(Figure 7f). Many of these mRNAs were gradually reduced in
transition from normal to recruited and to tumor states,
correlating with loss of oligodendroglial character (Aspa, Mobp,
Tfr, Mog), evasion of cell death (Mal, Ndrg1, Gjb6, Gpr37),
maintenance of undifferentiated phenotype (Mal, Ndrg1, Efhd1,
Kndc1, Ermn), cell-cell and cell-matrix interactions (Thbs3,
Tppp3, Itih3), and cell signaling (Ppp1r14a, Gja1). Cnn2 mRNA
was specifically reduced on the polysomes of recruited cells as
compared to both normal and tumor olig2 cells, while Nupr1,
Aldh1l1, Lcn2, Papss2, and Igf2bp2 mRNAs were specifically
increased in this population (Figure 7f).
Discussion
RCAS/tv-a system allows to closely model the biology and
histopathology of human oligodendrogliomas; although we have
not performed direct comparisons between our mouse model and
human glioma classifications, in many ways, hPDGFb-driven
murine gliomas may mimic the proneural subclass of human
GBMs [6–8]. Our data suggests that olig2-expressing cells
recruited in PDGF-induced murine gliomas can have similar
morphologic, proliferative and functional characteristics as olig2-
expressing tumor cells derived from the cell-of-origin, with the
caveat that a part of the similarity between the recruited and
tumor olig2 cells may stem from their proliferative behavior.
Extensive similarities between polysome-associated transcriptome
of recruited versus glioma olig2 cells call for further evaluation of
the precise definitions and criteria applied to terms ‘‘tumor’’ and
‘‘normal’’, and indicate similar gene expression character of these
cells. Furthermore, tumor suppressor loss and acquisition of
mutations typically found in human gliomas allow these murine
recruited cells to occupy large areas of the tumor and at times
become the predominant cellular component of the glioma mass,
completely independent of the cell-of-origin. Thus, the clonal
expansion that overtakes glioma bulk during tumor progression
need not be derived from glioma cell-of-origin.
Transformation is the process of self-autonomous acquisition of
the sufficient oncogenic alterations that change a normal cell into
the tumor cell. Unlike epithelial cancers, the ‘‘normal’’ or stromal
component of a glioma is composed of cells of the same lineage as
the tumor cells. The inherent implication of this observation is that
extracellular factors that promote glioma tumor cell growth may
similarly affect glioma stroma. In our glioma model, initially
normal recruited cells not derived from the glioma-initiating cell-
of-origin can be stimulated by hyperproduction of a growth factor
receptor ligand, induced to proliferate, and driven to acquire
various genetic aberrations and aberrant expression profiles as
gliomas progress, presumably because of the tumor microenvi-
ronment created by the progeny of the cell-of-origin. The process
of acquisition and selection for such genetic and/or epigenetic
alterations due to the pressures of the glioma microenvironment
may be better termed ‘‘corruption’’. Although it is not known how
frequently recruitment and subsequent corruption occurs in
human PDGF-driven gliomas, gliomas in general or in other
tumor types, our data indicates that this process may not be
limited to hPDGFb-induced murine gliomas. As such, human
gliomas that appear to be comprised of two or more genetically
unrelated clones, or recurrent patient gliomas that lack the genetic
alterations present in the originally resected tumors subjected to
therapeutic stress, may be examples of these processes. Although
similar processes have not been described in vivo,a nin vitro line of
evidence from the colon cancer cell lines suggested that one of the
mechanisms of how cancer cells bypass senescence may be related
to their potential for continuous ‘‘clonal diversification’’, even
within the what is perceived a clonal population of cancer cells, not
affected by native stromal environment [45].
The process of corruption would thus occur if the tumor
microenvironment initially drive proliferation and induce the
stem-like character in both progeny of the cell-of-origin and the
recruited cells. In hPDGFb-driven gliomas there is evidence for
both - tumor cells secrete proliferative growth factors, inflamma-
tory cells secrete cytokines, and endothelial and inflammatory cells
secrete nitric oxide that activates the Notch signaling pathway,
promoting the stem-like character [46]. Such environment affects
cells within the tumor regardless of whether they are derived from
the glioma-initiating cell-of-origin or not. This notion is further
supported by the analysis of expression array data using the
bacTRAP olig2 RP-eGFP reporter system and immunostaining,
which suggest that recruited olig2 cells can acquire expression of
GFAP and vimentin and increase the expression of nestin as
compared to the tumor olig2 cells, triple co-expression of which is
considered to be typical for the bona fide neural stem cells.
Methods
Ethics Statement
All animal experiments were conducted using protocols
approved by the Institutional Animal Care and Use Committees
of Memorial Sloan-Kettering Cancer Center. The approved
protocols are: 00-11-189(MSKCC, last approved 3/15/2010).
Vectors, cell culture and Ntv-a tumor induction. RCAS-
hPDGFb-HA-SV40-eGFP (RCAS-PSG) containing human
PDGFb with partially deleted 59UTR, RCAS-hPDGFb-HA,
RCAS-Cre and RCAS-mRFP-SV40-Ras (RCAS-RSR) vectors
were transfected into DF-1 chicken cells (ATCC) [14,37]. DF1
cells transfected with RCAS-PSG were FACS-sorted to select 15%
brightest eGFP-expressing cells and cultured in 10% FBS-DMEM
media under standard conditions. For tumor induction, transfected
DF1 cells were trypsinized, centrifuged and injected into the brain
parenchyma of Ntv-a mice that transgenically express RCAS-
bindingtv-areceptorafterthenestinpromoter,atpost-nataldays0–
2. At 3 weeks post-injection, injected Ntv-a mice were weaned and
observed daily for the appearance of brain tumor symptoms.
Tissue collection and processing. Experiments involving
mice were performed in accordance with the regulations set by the
MSKCC IACUC committee. Upon the appearance of brain tumor
symptoms (e.g. poor grooming, lethargy, macrocephaly, hydro-
cephaly, hemiparesis, weight loss), mice were anesthetized by an
intraperitonealinjectionof 1 mg/kgNembutal solutionor ketamine
(150 mg/kg)/xylazine (15 mg/kg) cocktail and underwent trans-
cardiac perfusion with 10 ml ice-cold heparin normal saline,
followed by 10 ml of ice-cold 4% paraformaldehyde. Brain tissue
was extracted and post-fixed for 30 minutes in ice-cold 4%
paraformaldehyde, transferred into 30% sucrose at 4uC for
cryoprotection, embedded using the OCT compound, frozen on
dry ice and stored at 280uC until sectioned. A small subset of
animals were sacrificed using CO2, their brain tissue extracted and
fixed for 3 days in 4% paraformaldehyde at 4uC, and subsequently
processed using standard paraffin embedding and processing
techniques.
bacTRAP technology. Normal olig2 progenitors were
collected from three replicates of pooled cortices of three olig2
RP-eGFP bacTRAP reporter mice. Mouse gliomas induced by
injection of a non-fluorescent RCAS-hPDGFb [14] or by
transplantation of murine glioma cells derived from Ntv-a
gliomas induced by the non-fluorescent RCAS-hPDGFb were
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immunoprecipitated; each tumor was processed as a separate
sample. Briefly, mouse tissues were collected into ice-cold
cyclohexamide-containing buffer, homogenized, cells were lysed
in NP-40 and DHPC-containing buffer, centrifuged at 20,000 g
for 15 min, supernatant incubated with anti-eGFP-conjugated
protein G beads 30 min at 4C, washed and RNA collected using
Trizol reagent as per manufacturer’s instructions [31,32]. RNA
was purified, concentrated using Qiagen RNeasy kit, its quality
confirmed by Agilent Bioanalyzer, 15 ng per sample amplified
using Affymetrix Two-Cycle Amplification kit and hybridized to
Affymetrix 430 mouse 2.0 chips as described in [31,32].
Microarray analysis. Data was analyzed using Genespring
GX10 software, as described in the text and in [31,32]. Briefly,
samples were normalized using GCRMA, filtered to remove probe
sets with low intensity, and analyzed using ANOVA (p,0.05) with
SNK post-hoc and Benjamini and Hochberg FDR multiple testing
correction. Probe quality, Pearson’s correlation, hierarchical
clustering, heatmaps, gene profile plots were generated using
Genespring GX10 software. Pathway analysis was performed
using Ingenuity as per manufacturer’s instructions. The mRNA
microarray data generated by this study are available through the
NCBI Gene Expression Omnibus (GEO) (accession number
GSE30016, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE30016).
Cell Sorting and transplantation of murine glioma
cells. Glioma-bearing brains were extracted from anesthetized
mice, gliomas excised from surrounding brain parenchyma,
dissociated using a mix of collagenases as previously described,
and sorted using MoFlo FACS sorting. Various numbers of cells
(1,000–500,000) resuspended in sterile 1X PBS were injected into
brain parenchyma of neonatal immunonaive mice of various
genetic backgrounds, or stereotactically transplanted into
anesthetized adult SCID mice.
PCR on tumor sections. Mouse glioma sections were
scraped from slides and lyzed with 0.05% SDS buffer. Genomic
DNA was extracted using phenol-chloroform according to
standard techniques, and precipitated at 220uC overnight. Prior
to PCR for hPDGFb, DNA was heated at 56uC for 2 hours or for
5 min at 100uC, concentration measured, and equal amounts of
DNA added to PCR reactions. PCR reactions for human PDGFB,
Pten, and the Ink4a/Arf locus were performed using previously
published primers. Control GAPDH reactions were performed in
the same PCR mix. Data was obtained using GelDoc Software.
qPCR on tumor sections. DNA was extracted using 0.05%
SDS buffer as above; Roche primers were used to detect ampli-
fications of mouse EGFR (Set#6, AGAACCAGTCCAGATCGG
and AAGGATGTGTAAGGGACC; Set#27, ACACTTGCCC-
AGAAAAATG and AGGTGGGATTGTACAGAG) or mouse
IGFR (Set#67, CTCACAGGTGGACAGTGC and ATGCCCC-
AGGGCCTGTAA; Set#104, GAGAATTTCCTTCACAATT
and CACTTGCATGACGTCTCTC). Pten qPCR was performed
using previously published primers [37].
RT-PCR on FACS-sorted cells. Total RNA from sorted cells
was extracted using the Qiagen RNeasy kit and resuspended in 30-
50 ul of DEPC-treated water. About 5 ug of total RNA was
reverse-transcribed using the SuperScriptIII Reverse strand
synthesis kit from Invitrogen. Quantitative RT-PCR was
performed using primers for human PDGFb and mouse actin as
a control.
Immunohistochemistry. Cryogenically processed murine
glioma tissue was sectioned at 7 microns, washed with PBS,
blocked with 10% serum in PBS using 0–0.3% TX-100 for
polyclonal rabbit/goat or MOM kit for monoclonal mouse and rat
antibodies, and incubated with primary antibodies for 1 hour at
room temperature or overnight at 4C. The primary antibodies
included PDGFRa and PTEN from Cell Signaling; olig2, Ki67,
hNA and EGFR from Abcam; NeuN from Chemicon; HA from
Santa Cruz; and eGFP from Molecular Probes. Secondary
fluorochrome-conjugated antibodies (Alexa555, Alexa488, and
Alexa647) were applied for 1 hr at room temperature, slides
washed several times, counterstained with DAPI (1:3000 of a
1 mg/ml 1X PBS solution), mounted in 70% glycerol,
coverslipped and photographed with inverted fluorescent or
confocal Leica microscopes.
Cell Sorting and transplantation of murine glioma
cells. Glioma-bearing brains were extracted from anesthetized
mice, gliomas excised from surrounding brain parenchyma,
dissociated using a mix of collagenases as previously described,
and sorted using DAKO-Cytomation MoFlo FACS sorters for
eGFP expression. Samples were gated to exclude debree, dead
cells and doublets. Various numbers of cells (1,000–500,000)
resuspended in sterile 1X PBS were injected into the brain
parenchyma of neonatal immunonaive mice of various Ntv-a
genetic backgrounds, or stereotactically transplanted into
anesthetized adult SCID mice, using Hamilton syringe. CD133
(eBioscience) staining of acutely dissociated murine glioma cells
was done as per manufacturer’s instructions; CD133 antibody was
used at a 10-fold lower concentration based on titration. Single- or
double-sorted CD133-positive cells were transplanted as described
above. Cell-mixing experiments were performed using double-
sorted eGFP-positive progeny and double-sorted CD133-positive
recruited cells, which were mixed just prior to transplantation, and
injected using Hamilton syringe.
Fluorescent in-situ hybridization. RCAS DNA was
fragmented using nick translation kit, labeled with biotin, and
digested to 500 bp-2 kb probe size. Resulting probes were
denatured at 80uC and applied to tumor sections blocked with
salmon sperm DNA for an overnight incubation at 37uC. Slides
were washed with 2X SSC-50% formamide solution at 45uC,
signal amplified according to standard techniques using TSA kit,
and revealed with Alexa488 and Alexa555. Slides were
counterstained with DAPI (1:3000 of 1 mg/ml PBS solution),
mounted, coverslipped and photographed using inverted
fluorescent or confocal Leica microscopes.
Statistical analysis. Kaplan-Meyer curves for mouse glioma
latency were made using Prism4 software and analyzed with
standard log rank test, or using R. The p value was determined to
be less than 0.001 for survival curves of Ntv-a wild-type vs. Ntv-a
Arf
-/- mice injected with RCAS-PSG vs. Ntv-a Ink4a/Arf
-/- Pten
fl/fl
mice injected with RCAS-PSG and RCAS-Cre. Survival curves
for Ntv-a wild-type vs. Ntv-a Ink4a
-/-, or for Ntv-a Ink4a/Arf
-/- vs.
Ntv-a Arf
-/-, were not statistically different from each other.
Statistical analysis of other data, including percentages of eGFP-
positive cells in different murine Ntv-a backgrounds and
percentages of Ki67-positive cells in PTK787-treated murine
gliomas, was performed using unpaired two-tailed t-tests and F-
tests in Prism4.
Supporting Information
Figure S1 Background information for RCAS-PSG-in-
duced Ntv-a gliomas. (a–d) H&E-stained paraffin sections of
low-grade Ntv-a gliomas containing secondary structures of
Scherer characteristic of human gliomas: subpial accumulations
of tumor cells (a), white matter tracking (b), perivascular (c) and
perineuronal satellitosis (d). Red arrowheads indicate glioma cells.
(e,f) Expression of eGFP in high-grade Ntv-a Arf
-/- murine
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hPDGFb infection. eGFP+ and eGFP- glioma cells were sorted
and used for real-time PCR. (Ntv-a Arf
-/- high-grade gliomas were
used in lieu of wild-type because wild-type Ntv-a gliomas
contained very few recruited cells.) (f) shows normal murine Ntv-
a brain, total mixed tumor cell population, and sorted progeny or
recruited cell fractions for Ntv-a gliomas shown in (e).
(TIF)
Figure S2 Expression of eGFP in progeny cells of low-
and high-grade Ntv-a gliomas correlates with hPDGFb
expression. Images (a–d) show native eGFP, anti-HA staining
for the hemagglutinin tag on viral hPDGFb and corresponding
composites in low-grade (a,b) and high-grade (c,d) Ntv-a gliomas.
Overall expression of eGFP and hPDGFb correlates on a cell-to-
cell basis, but relative amounts of expression of eGFP and
hPDGFb proteins may differ. (e,f) High-magnification composites
showing correlation of hPDGFb and eGFP expression in
pseudopalisade regions of high-grade Ntv-a gliomas. Asterisks in
(e,f) indicate pseudopalisade lumens.
(TIF)
Figure S3 Validation of the bacTRAP olig2 RP-eGFP
system in Ntv-a gliomas. (a) olig2 (red) and nestin (green)
immunostaining of Ntv-a wild-type mouse RCAS-hPDGFb-
induced gliomas, showing expression of olig2 in most tumor cells.
(b) Experimental design to label and isolate olig2 tumor cells and
olig2 recruited cells. (c,d) DAPI-stained frozen sections of murine
gliomas induced in bacTRAP olig2 RP-eGFP reporter mice, with
olig2 and eGFP stains shown in red. bacTRAP olig2 RP-eGFP mice
accurately recapitulate expression of olig2 and eGFP.
(TIF)
Figure S4 Tumor suppressor loss in hPDGFb-induced
Ntv-a gliomas results in shorter glioma latency, in-
creased grade and larger numbers of recruited cells. (a)
H&E-stained section of an Ntv-a glioma containing pseudopalisad-
ing necrosis and microvascular proliferation, red arrowheads. (b)
Tumor incidence and presence of low- and high-grade glioma
structures in gliomas of various Ntv-a mouse backgrounds, induced
with RCAS-PSG with or without RCAS-Cre. X-axes color-coding
corresponds to color-coding of Ntv-a mouse strains in the Kaplan-
Meyer analysis in Figure 2. (c) Correlations between PTEN
immunostaining (IHC) and Pten LOH (PCR for Pten alleles on
tumor cell DNA extracted from mouse glioma sections) during
glioma progression in Ntv-a gliomas heterozygous targeted for
Ink4a, Arf and Pten tumor suppressor loss at glioma initiation. DNA
concentrations were measured, and equal amounts of DNA were
loaded per tumor sample. Normal, uninjected murine Ntv-a brain;
PDGF and PDGF/Cre, murine gliomas induced in Ntv-a mice
homozygous targeted for Ink4a, Arf and Pten loss at glioma
initiation. All other samples are derived from Ntv-a Ink4a/
Arf
+/-Pten
+/fl mice injected with RCAS-PSG and RCAS-Cre. Note
lack of Pten expression in some murine gliomas that retain Pten at
the genetic level. (d,e) PTEN expression is absent in Ntv-a GBMs
heterozygous targeted for Ink4a, Arf and Pten tumor suppressor loss
at glioma initiation.
(TIF)
Figure S5 The recruitment phenomenon is not limited
to murine gliomas characterized by paracrine hPDGFb
signaling: K-Ras-driven Ntv-a gliomas with tumor
suppressor loss contain recruited cells. Quantification
of recruited cells and comparison of glioma latency in
GBMs with large regions of recruitment or progeny cell
contribution. (a) Construction of RCAS-mRFP-SV40-
KRasG12D vector. (b,c) mRFP expression DF1 cells transfected
with RCAS-mRFP-SV40-KRasG12D. (d,e) Expression of mRFP
in frozen sections of an Ntv-a GBMs induced by injection of
RCAS-mRFP-SV40-KRasG12D and RCAS-Cre, mRFP immu-
nostaining. Note the presence of cells not expressing mRFP. (f)
Immunostaining for RP-eGFP expression (red) in recruited olig2
cells in transplanted gliomas arising in bacTRAP olig2 RP-eGFP
mice induced by transplantation of Ras-driven Pten-deleted
murine glioma cells. (g) PDGFRa stain (red) of an Ntv-a glioma
induced by RCAS-K-RasG12D and RCAS-Cre. Note absence of
PDGFRa expression in tumor cells. (h) RP-eGFP is expressed in
olig2 tumor cells contributing to pseudopalisades of transplanted
gliomas induced by the hPDGFb-expressing murine glioma cells
and arising in bacTRAP olig2 RP-eGFP mice. (i) Tumor latency for
Ntv-a gliomas containing large regions of progeny or recruited cells
induced in Ntv-a mice heterozygous targeted for loss of Ink4a, Arf
and Pten by RCAS-PSG and RCAS-Cre. While there is a small
but statistically significant difference with respect to latency
medians (two-tailed unpaired Student’s t-test, p,0.006), latency
variances largely overlap (F test). (j) FACS plots of 4 Ntv-a gliomas
heterozygous targeted for tumor suppressor loss of Ink4a, Arf and
Pten at glioma initiation, containing large numbers of recruited cell
pseudopalisades. Percentages of recruited cells vary from 0.91% to
36.8%. (k) Graph shows variability of contribution from the
eGFP-expressing progeny and the eGFP-negative recruited cells
across various Ntv-a mouse strains, including Ntv-a gliomas
containing large regions of recruitment.
(TIF)
Figure S6 hPDGFb-induced Ntv-a gliomas show region-
al expression of growth factor receptors important in
human glioma biology, expression of which in recruited
cells may be associated with low level amplifications in
some cases. (a–d) Ntv-a gliomas induced in Ntv-a Ink4a/
Arf
+/-Pten
+/fl mice injected with RCAS-PSG and RCAS-Cre
stained with IGFR (red), EGFR (pink) (a,d) or PDGFRa (red)
(b,c). Glioma regions predominantly derived from progeny cells
(a,b) express PDGFRa; expression of EGFR and IGFR is limited
to perivascular areas. (c,d) Adjacent sections stained with
PDGFRa and EGFR (red) show regional expression of growth
factor receptors; eGFP omitted for easier view. (e) FISH for IGFR
(green) and EGFR (red) on Ntv-a GBMs with large areas of
recruitment and high EGFR expression. Panels show a neuron,
EGFR-expressing non-amplified GBM with extensive recruitment,
and EGFR-expressing GBM with EGFR amplification in the
recruited cells. (f) Summary of mEGFR FISH performed on
EGFR-expressing GBMs with large areas of recruitment. Gliomas
containing more than 15% of cells with $3 mEGFR signals are
marked with an asterisk (amplified). (g,h) real-time qPCR on DNA
extracted from sections of mouse Ntv-a GBMs containing large
areas of recruitment (blue squares) highly expressing EGFR.
Primers for mEGFR kinase domain (g) or intron region of
mEGFR (h) were designed by Roche; graphs show fold increase
over normal EGFR copy number (Ø); gliomas with large areas
composed of progeny cells (green squares) were used to establish
range of variability of primer noise. Gliomas marked with asterisks
were considered amplified, and gliomas marked with arrows
appeared amplified by both primer pairs, potentially representing
tumors with larger chromosomal amplifications.
(TIF)
Figure S7 Recruited cells can initiate gliomas upon
transplantation and can be serially passaged in mouse
hosts. (a–d) H&E-stained sections depicting histology of mouse
gliomas induced by transplanting recruited cells. (e–g) Purification
Transformed Recruited Cells
PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e20605of recruited cells from Ntv-a Ink4a/Arf
+/-Pten
+/fl mice injected with
RCAS-PSG and RCAS-Cre; (h) DAPI-stained frozen section of a
glioma induced by recruited cells; note absence of cells with virally
encoded eGFP. (i–l) Gliomas induced by the recruited cells could
be serially passaged in mice. (i–k), FACS plots of gliomas induced
by serial transplantation of recruited cells into mouse hosts at
passaging; recruited glioma cells were single purified between
passages. (l) DAPI-stained section of a transplanted glioma
induced by recruited cells, showing absence of progeny cells with
virally encoded eGFP.
(TIF)
Figure S8 Immunohistochemical analysis of murine
gliomas induced by transplanting recruited cells. Images
(a–l) show native eGFP and immunostaining for Ki-67 (a,b), olig2
(c,d), GFAP (e,f), nestin (g,h), VEGFR (i), YKL40 (j) and CD44
(k,l).
(TIF)
Figure S9 Single-sorted CD133-positive cells are con-
taminated by low numbers of progeny cells and give rise
to gliomas containing small numbers of progeny. FACS
plot of an Ntv-a GBM induced by RCAS-PSG and RCAS-Cre,
stained with CD133. Single-purified (b,c) CD133-positive cells are
recruited, but sorted fractions contain low numbers of progeny
cells. Double-purified CD133 cells are recruited (d). (b) PCR and
qPCR (c,d) analysis of sorted CD133-positive recruited cells and
eGFP-positive progeny, showing absence of viral integration. (e–j)
H&E and DAPI-stained sections of transplanted gliomas induced
by single-sorted eGFP-positive (e,h) or CD133-positive (f,g,i,j)
cells. Note the presence of contaminating progeny in transplanted
gliomas induced by single-sorted CD133-positive cell fractions.
(TIF)
Figure S10 Microarray analysis of normal olig2, re-
cruited olig2 and glioma olig2 cells indicates that
recruited cells are similar to glioma cells and differ
from normal progenitors. (a) Glioma induced by transplan-
tation of non-fluorescent hPDGFb-driven mouse glioma cells into
wild-type olig2 RP-eGFP bacTRAP reporters, showing transgenic
RP-eGFP expression and anti-eGFP stain (red). Note large numbers
of RP-eGFP-positive recruited cells. (b,c) Quality Controls
Metrics plot and Pearson’s correlation plot for Affymetrix arrays
for normal (N), tumor (T) or recruited (R) olig2 cells. (d)
Genespring GX10-generated profile plots showing averaged
normalized intensity values for 500 mRNAs most different
between glioma and normal olig2 cells (first plot), changing at
least two-fold (second plot) or at least five-fold (third plot) between
recruited olig2 cells and normal olig2 progenitor cells. (e) Principal
component analysis on mRNAs with ANOVA-tested mRNA set
removed. Note that all samples do not cluster well when the
ANOVA-tested set of mRNAs specifically changed in tumor olig2
cells versus normal olig2 cells is removed.
(TIF)
Table S1 The dilution table for transplanted double-
sorted recruited eGFP-negative cells. Incidence of gliomas
induced by transplanting double-purified eGFP-negative recruited
cell fractions derived from Ntv-a RCAS-PSG-induced mouse
gliomas homozygous or heterozygous deleted for Ink4a, Arf and
Pten at tumor initiation. Shown in the Table are numbers of large
tumors and smaller proliferative lesions arising in recipient mice.
(TIF)
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